Archived Webinar: ART Options and Treatment Decisions for Women of Reproductive Potential
ART Options and Treatment Decisions for Women of Reproductive Potential
Monica Gandhi, MD, MPH
Release date: March 26, 2019
Expiration date: March 26 19, 2020
No longer available for CME credit
Assessment of Needs
The webinar will go over the current options for antiretroviral regimens in women of reproductive potential and during pregnancy, with particular attention to pharmacokinetic changes and safety. Further, the presentation will go over recent data on neural tube defects with dolutegravir use in early pregnancy and the resultant changes in WHO guidelines for ART during pregnancy. Finally, the presentation will explore ways in which ART should be further studied in women throughout their lifespan, including during pregnancy and reproductive years.
On completion of this webinar, learners will be able to:
- Describe the recent data linking dolutegravir to possible neural tube defects
- Describe the recent guidelines (in high-income and low-income settings) for ART options in women of reproductive potential and pregnant women
- Understand ways in which the pharmacokinetics and safety profile of ART agents during pregnancy can be explored
- Provide practical tips for treating women with HIV during pregnancy or of reproductive potential
- Learn about new initiatives on including pregnant women in clinical trials of new medications
Who Should Attend
This advanced webinar is designed for clinical decision makers who are actively involved in HIV care and research.
This activity is also relevant for registered nurses, PharmDs, and other health professionals.
Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Dr Gandhi has no relevant financial affiliations to disclose. (Updated 03/12/19)
Dr Abrams has no relevant financial affiliations to disclose. (Updated 03/25/19)
CME Panner and Reviewer
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 03/25/19)
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Additional support has been provided by
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at registration“at”iasusa.org or 415-544-9400.
How to Claim Credit
- Start the Activity by clicking "START COURSE" located above.
Please note that the "START COURSE" will no longer be visible once you clicked it once.
- Watch the webinar here.
- Return to this page and follow this link to the evaluation form.
- Once you complete the evaluation, you will be directed to the online claim form, where you will record the number of hours that you participated in this activity. You must be logged in to your IAS–USA profile to claim credit. Please note: if you already have participated on the live webinar and have received CME credits, you will not receive additional credits from this activity.
- Your certificate will be available for you to print from your IAS–USA account immediately after you have submitted your claim form. To view your certificates, go to "My Activities" under your profile.